NCT07112287

Germline Testing for Predisposition to Myeloid Malignancies

RecruitingNAINTERVENTIONAL

Trial Details

Start: 2025-11-10Est. Completion: 2030-04-01

Enrollment target: 200 participants

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Contact

Christopher R Reilly, MDChristopherr_reilly@dfci.harvard.edu 407-443-6243

Other microbiome trials you might be interested in

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesPhase 1Recruiting

Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, AcuteLeukemia, Lymphocytic, Acute

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…

Bethesda, United StatesEst. completion Apr 30, 2029

View Trial →

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.